Abstract
Tinuvin 770 (BTMPS) is a non-competitive, use-dependent antagonist of nicotinic acetylcholine receptors (nAChRs). The drug is highly lipid soluble and as such it has the potential to act within the brain. Presently the ganglionic blocking drug mecamylamine is used almost exclusively to block central nAChRs upon peripheral administration. These experiments were designed to confirm the nAChR antagonism effectiveness of BTMPS in both peripheral (ganglionic stimulation) and central (locomotor activity and thermal nociceptive sensitivity) nicotinic system in vivo. BTMPS inhibited the expression of the pressor response produced by i.v. injection of the ganglionic stimulant DMPP in anesthetized rats. The inhibition dose-response profile appeared to be biphasic with the maximal inhibition occurring after administration of the 0.48 mg/kg dose of BTMPS. In rats acclimated to the test apparatus, nicotine increased different measures of locomotor activity, particularly at the 0.75 mg/kg dose. BTMPS pretreatment significantly inhibited the nicotine-induced increase in motor behaviors, again with a biphasic dose-response relationship. Lastly, nicotine elicited an antinociceptive response in rats (hot plate test). BTMPS almost completely blocked the antinociceptive responses to 1 and 1.5 mg/kg nicotine. On its own, BTMPS failed to decrease blood pressure and to decrease the nociceptive threshold. The drug also generally failed to alter locomotor activity. The use-dependent aspect of BTMPS-induced inhibition of nAChRs was evident in the drugs greater effectiveness in the presence of the highest doses of nicotine. Therefore, BTMPS can be considered as an alternative to or as a confirmatory drug for mecamylamine when inhibition of central nicotinic receptors is required.
Keywords: nicotinic receptor, tinuvin 770, nicotine, blood pressure, motor activity, antinociception, dmpp, autonomic ganglia
Current Alzheimer Research
Title: Functional Central Nicotinic Acetylcholine Receptor Antagonism by Systemic Administration of Tinuvin 770 (BTMPS)
Volume: 2 Issue: 2
Author(s): John H. Graham, Roger L. Papke and Jerry J. Buccafusco
Affiliation:
Keywords: nicotinic receptor, tinuvin 770, nicotine, blood pressure, motor activity, antinociception, dmpp, autonomic ganglia
Abstract: Tinuvin 770 (BTMPS) is a non-competitive, use-dependent antagonist of nicotinic acetylcholine receptors (nAChRs). The drug is highly lipid soluble and as such it has the potential to act within the brain. Presently the ganglionic blocking drug mecamylamine is used almost exclusively to block central nAChRs upon peripheral administration. These experiments were designed to confirm the nAChR antagonism effectiveness of BTMPS in both peripheral (ganglionic stimulation) and central (locomotor activity and thermal nociceptive sensitivity) nicotinic system in vivo. BTMPS inhibited the expression of the pressor response produced by i.v. injection of the ganglionic stimulant DMPP in anesthetized rats. The inhibition dose-response profile appeared to be biphasic with the maximal inhibition occurring after administration of the 0.48 mg/kg dose of BTMPS. In rats acclimated to the test apparatus, nicotine increased different measures of locomotor activity, particularly at the 0.75 mg/kg dose. BTMPS pretreatment significantly inhibited the nicotine-induced increase in motor behaviors, again with a biphasic dose-response relationship. Lastly, nicotine elicited an antinociceptive response in rats (hot plate test). BTMPS almost completely blocked the antinociceptive responses to 1 and 1.5 mg/kg nicotine. On its own, BTMPS failed to decrease blood pressure and to decrease the nociceptive threshold. The drug also generally failed to alter locomotor activity. The use-dependent aspect of BTMPS-induced inhibition of nAChRs was evident in the drugs greater effectiveness in the presence of the highest doses of nicotine. Therefore, BTMPS can be considered as an alternative to or as a confirmatory drug for mecamylamine when inhibition of central nicotinic receptors is required.
Export Options
About this article
Cite this article as:
Graham H. John, Papke L. Roger and Buccafusco J. Jerry, Functional Central Nicotinic Acetylcholine Receptor Antagonism by Systemic Administration of Tinuvin 770 (BTMPS), Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585747
DOI https://dx.doi.org/10.2174/1567205053585747 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Endothelial Cell Antibodies in Patients with Cerebral Small Vessel Disease
Current Neurovascular Research Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Personalizing Psychological Treatment Along the IBD Journey: From Diagnosis to Surgery
Current Drug Targets Induced Pluripotent Stem Cells as a Model for Accelerated Patient- and Disease-specific Drug Discovery
Current Medicinal Chemistry A Sensitive HPLC-MS/MS Method for the Quantification of Selegiline in Beagle Dog Plasma: Application to a Pharmacokinetic Study
Current Pharmaceutical Analysis Adenosine A2A Receptors in Psychopharmacology: Modulators of Behavior, Mood and Cognition
Current Neuropharmacology Immunomodulation in Trichinellosis: Does Trichinella Really Escape the Host Immune System?
Endocrine, Metabolic & Immune Disorders - Drug Targets Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Subject Index to Volume 1
Current Pharmacogenomics Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise
CNS & Neurological Disorders - Drug Targets Budesonide and Phenethyl Isothiocyanate Attenuate DNA Damage in Bronchoalveolar Lavage Cells of Mice Exposed to Environmental Cigarette Smoke
Current Cancer Drug Targets Molecularly Imprinted Sol-Gel Materials for Medical Applications
Current Topics in Medicinal Chemistry Synthesis of New Benzimidazole and Benzothiazole Disulfide Metal Complexes as G-quadruplex Binding Ligands
Anti-Cancer Agents in Medicinal Chemistry Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) Electroporation: An Avenue for Transdermal Drug Delivery
Current Drug Delivery Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Neuronal Death in Amyotrophic Lateral Sclerosis (ALS): What Can We Learn from Genetics?
CNS & Neurological Disorders - Drug Targets Patent Review
Combinatorial Chemistry & High Throughput Screening Synthesis, Biological Evaluation and Molecular Docking Studies of Novel Di-hydropyridine Analogs as Potent Antioxidants
Current Topics in Medicinal Chemistry Glutamate Receptors in Microglia
CNS & Neurological Disorders - Drug Targets